FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:396-397 February 5, 1998 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Nevirapine (Viramune), manufactured by Roxane Laboratories, is a non-nucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. Nelfinavir (Viracept), manufactured by Agouron Pharmaceuticals, inhibits the HIV-1 protease enzyme. Unfortunately, these medications have similar generic and brand names, as well as available tablet strengths (nevirapine, 200 mg; nelfinavir, 250 mg). Therefore, the potential for drug-dispensing errors is substantial.

Within a two-week period, two patients with HIV infection presented to our outpatient HIV clinic because they were concerned about their medication. One patient, who had received a new prescription for nelfinavir (250 mg per tablet; three tablets . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.